| Accession |
PRJCA025384 |
| Title |
First-line Penpulimab and Anlotinib with Nab-paclitaxel/Gemcitabine (PAAG) in Metastatic Pancreatic Cancer: A Prospective, Multicentre, Biomolecular Exploratory, Phase II Trial |
| Relevance |
Medical |
| Data types |
Transcriptome or Gene expression
Genome sequencing
|
| Organisms |
Homo sapiens
|
| Description |
Pancreatic cancer (PC), a common malignant tumor of the digestive system, has shown a gradual increase in incidence and mortality worldwide. Currently, systemic chemotherapy remains the cornerstone of treatment for advanced metastatic pancreatic cancer (mPC), while overall survival (OS) does not exceed one year. Immune checkpoint inhibitors (ICIs) have transformed cancer treatment in the last decade, their clinical benefits in PC remain to be substantiated. Both the CISPD3 study and the PRINCE study suggest that the combination of chemotherapy and ICI in PC can improve the ORR, reaching approximately 50%. This indicates that the combination of immunotherapy and chemotherapy has certain potential clinical significance. The interaction between the activation of angiogenic signalling pathways and the suppression of tumor immunity has been validated. For instance, patients with advanced intrahepatic cholangiocarcinoma (ICC) received a combination of toripalimab, lenvatinib, and gemcitabine plus oxaliplatin (GEMOX), reaching a breakthrough ORR of 80%. Considering the similar tumor microenvironment of gastrointestinal tumors, it is reasonable to combine anti-PD-1 therapy with antiangiogenic drugs and chemotherapy in mPC. Herein, we report the clinical and translational results of a prospective, multicentre, single-arm, phase 2 trial for the first-line treatment of patients with mPC who received PAAG. This clinical study was accompanied by multiomics profiling to identify multiple distinct and treatment-specific biomarkers. |
| Sample scope |
Multiisolate |
| Release date |
2024-04-18 |
| Publication |
| PubMed ID |
Article title |
Journal name |
DOI |
Year |
| 38844468
|
First-line penpulimab (an anti-PD1 antibody) and anlotinib (an angiogenesis inhibitor) with nab-paclitaxel/gemcitabine (PAAG) in metastatic pancreatic cancer: a prospective, multicentre, biomolecular exploratory, phase II trial
|
Signal transduction and targeted therapy
|
10.1038/s41392-024-01857-6
|
2024
|
|
|
| Biomaterial provider |
The Comprehensive Cancer Center, Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School, Nanjing University & Clinical Cancer Institute of Nanjing University |
| Grants |
| Agency |
program |
Grant ID |
Grant title |
| National Key Research and Development Program of China
|
|
2020YFA0713804
|
|
| Special Fund of Health Science and Technology Development of Nanjing
|
|
YKK20080
|
|
| Fundings for Clinical Trials from the Affiliated Drum Tower Hospital, Medical School of Nanjing University
|
|
2023-LCYJ-PY-29
|
|
|
|
| Submitter |
Juan
Du (juandunjglyy@163.com)
|
| Organization |
Nanjing Drum Tower Hospital, Affiliated Hospital of Medical School |
| Submission date |
2024-04-18 |
